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Abstract
Background: Youth with type 1 diabetes (T1D) have normal or elevated High- Density 
Lipoprotein Cholesterol (HDL- C), however, the function of HDL, partly mediated by 
the	HDL	proteome,	may	be	impaired.	Metformin	can	be	used	as	an	adjunct	therapy	in	
youth with T1D, but its effects on the HDL proteome are unknown.
Objective: To determine the effect of metformin on the HDL proteome.
Subjects: Youth	 (12–	20	 years	 old)	 with	 T1D	 who	 had	 a	 BMI	 >	 90th	 percentile,	
HbA1c	>	8.0%	and	Tanner	stage	5.
Methods: Double-	blinded,	placebo-	controlled	randomized	sub-	study.	We	examined	
the effects of metformin (n = 25) or placebo (n = 10) after 6 months on HDL proteome. 
Changes	in	HDL	proteins	were	measured	by	data-	independent	acquisition	(DIA)	mass	
spectrometry	 and	 compared	between	 treatment	 groups.	As	 a	 secondary	outcome,	
associations between proteins of interest and the most studied function of HDL, the 
cholesterol efflux capacity (CEC), was examined.
Results: The relative abundance of 84 HDL- associated proteins were measured. Two 
proteins were significantly affected by metformin treatment, peptidoglycan recogni-
tion	protein	2	(PGRP2;	+23.4%,	p	=	.0058)	and	alpha-	2-	macroglobulin	(A2MG;	+29.8%,	
p	=	.049).	Metformin	did	not	significantly	affect	CEC.	Changes	in	affected	HDL	pro-
teins did not correlate with CEC.
Conclusions: Despite having little effect on HDL- C, metformin increased PGRP2 
and	A2MG	protein	on	HDL	in	youth	with	T1D,	but	had	no	significant	effect	on	CEC.	
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1  |  BACKGROUND
Type 1 diabetes (T1D) is associated with an increased risk of cardio-
vascular disease (CVD).1 This CVD risk is evident even in children with 
T1D and can manifest as increased carotid intima- media thickness, 
increased pulse wave velocity, and decreased brachial artery disten-
sibility.2	Among	the	main	risk	factors	that	contribute	to	CVD	risk	are	
dyslipidemia, obesity, insulin resistance and poor glycemic control.1 
Dyslipidemia has traditionally been defined as low HDL- cholesterol 
(HDL- C), elevated triglycerides (TG), and high LDL- cholesterol (LDL- C). 
The relationship between HDL- C and CVD risk has been somewhat 
enigmatic. While epidemiological studies clearly demonstrate an in-
verse correlation with CVD outcomes, pharmacological manipulation 
of HDL- C has repeatedly failed to produce clinical benefit. Recent ev-
idence suggests that the function of HDL is not directly linked to its 
cholesterol content, therefore the presence of dysfunctional HDL may 
not be accounted for in the traditional HDL- C measure.3-	5
The functions of HDL are driven by the protein and lipid compo-
nents that constitute the complex HDL particle. One of the main func-
tions of HDL is the reverse transport of cholesterol from the arteries to 
the liver, which initiates with the efflux of cholesterol from peripheral 
tissues. This is often measured using an in vitro assay of cholesterol 
efflux capacity (CEC) and has been associated with cardiovascular 
events.6 HDL is also involved in atherosclerosis prevention by inter-
fering with coagulation, inflammation, and the complement pathway.7 
Our group has previously published that youth with T1D have lower 
CEC compared to healthy controls.3 Furthermore, we have shown that 
youth	with	T1D	have	smaller	size	HDL,	which	correlated	with	markers	
of insulin sensitivity,3 and less cholesterol distributed as large buoyant 
HDL- C on fast protein liquid chromatography, which correlated with 
hyperinsulinemic- euglycemic clamp- assessed insulin sensitivity.8
Based	on	our	previous	work,	we	hypothesized	that	metformin,	
which we previously demonstrated improves insulin sensitivity in 
youth with T1D,9,10 could change the protein cargo on HDL and sub-
sequently improve HDL function in youth with T1D. Our objective 
was to determine the effect of metformin on the HDL proteome in 
youth	with	T1D.	As	a	secondary	outcome,	we	examined	whether	the	
changes in protein abundance were associated with changes in the 
CEC, as an indicator of HDL function.
2  |  MATERIAL S AND METHODS
This	project	utilized	blood	samples	 that	were	collected	during	 the	
“T1D	Exchange	Clinic	Network	Metformin	RCT	Study	Group”	trial,	
a double- blind, placebo- controlled clinical trial assessing metformin 
usage as an adjunct therapy in obese adolescents with T1D. The de-
sign and the results of the main clinical trial have been previously 
described.11 In summary, this trial was conducted in 26 clinical sites 
of the T1D Exchange Clinic Network. Eligibility criteria for inclusion 
in this trial included: age 12– 20 years old, diagnosis of T1D, on treat-
ment	with	insulin	for	at	least	1	year,	BMI	at	or	above	the	85th	per-
centile based on CDC growth charts, total daily insulin dose of at 
least	0.8	units/kg/day,	HbA1c	values	at	enrollment	of	7.5%–	10.0%	
and	checking	blood	glucose	at	least	three	times	a	day.	A	total	of	140	
adolescents (aged 12.1– 19.6 years old) were enrolled in this study.
2.1  |  Participants
For the current proteomic project, our inclusion criteria included 




tial effects of different stages of pubertal development on protein 
cargo of HDL. We selected heavier participants and those with sub-
optimal glycemic control, given the expected lower insulin sensitiv-
ity and potentially enhanced benefit from metformin treatment. Of 
the eligible participants, the core lab randomly selected 25 partici-
pants with T1D who were treated with metformin for 6 months and 
matched them for age and sex with 10 participants with T1D treated 
with placebo for 6 months.
The T1D Exchange Biobank studies are governed by individual 
site institutional review boards. Qualifying participants provided 
consent or assent as age- appropriate and parents provided consent 
for participants <18 years old.
2.2  |  Clinical variables
Fasting blood samples were collected for analysis of a lipid profile 
(total cholesterol, high- density lipoprotein cholesterol [HDL- C], low- 
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2.3  |  Proteomics experiments
The preparation of serum samples for the proteomics experiments 
was performed as previously described.13,14 In brief, (1) purification 
of	HDL	from	serum	using	size-	exclusion	chromatography;	(2)	pooling	
of	all	 the	HDL	containing	 fractions;	 (3)	 application	of	 lipid-	binding	
resin to pooled HDL; (4) washing of HDL on the resin in order to 
remove contaminating proteins; (5) digestion of resin- bound HDL 
with	trypsin	(overnight	37°C);	(6)	washing	of	the	resin	in	order	to	col-
lect tryptic peptides; (7) reduction and carbamidomethylation (DTT 
and iodoacetamide, respectively); and (8) desalting of samples using 




tectable	by	MS	 for	 the	analysis	of	a	 sample	pool	 from	all	 the	par-
ticipants (with an equal amount of proteins combined). The pooled 
sample	 was	 analysed	 in	 data-	dependent	 acquisition	 (DDA)	 mode.	
Then, we ran each sample individually via label- free Sequential 
Window	Acquisition	of	All	Theoretical	Mass	Spectra	(SWATH)	data-	
independent	acquisition	(DIA)	to	quantify	each	of	these	proteins	in	
the samples. Specifically, the peptides in each sample were dissolved 
into	20	µl	of	0.1%	 formic	acid.	For	 spectra	 library	generation,	 the	
pooled	sample	was	loaded	onto	a	C18	Trap	column	(Waters	Acquity	
UPLC	 Symmetry	 C18	 NanoAcquity	 10	 K	 2G	 V/M,	 100	 A,	 5	 μm, 
180 μm x 20 mm) at 15 µl/min for 4 min. Peptides were separated 
with	an	analytical	column	(Waters	Acquity	UPLC	M-	Class,	peptide	
BEH	C18	 column,	 300	A,	 1.7	μm, 75 μm x 150 mm) which had a 





buffer B to equilibrate the column for 20 min. The TripleTOF 6600 






acquisition, each of the samples was injected individually into the 
same	NanoUPLC-	MS/MS	system	but	acquired	by	repeatedly	cycling	
through	32	consecutive	25-	Da	precursor	isolation	windows,	gener-
ating time- resolved fragment ion spectra for all the analytes detect-
able	within	the	400–	1200	m/z	precursor	range.
2.4  |  Proteomics data analysis
In order to generate the spectra library, raw mass spectra files after 
DDA	 acquisition	 of	 the	 pooled	 sample	 were	 submitted	 for	 com-
bined	searches	using	Protein	Pilot	version	5.0	software	(Sciex)	utiliz-
ing the Paragon and Progroup algorithms15 and the integrated false 
discovery rate (FDR) analysis function.16	MS/MS	data	were	searched	
in the NCBI Homo Sapiens of the Uniprot- Sprot database containing 
20,316	entries	(downloaded	on	June	2,	2015).	Carbamidomethylation	
was set as a fixed modification on cysteine and trypsin was selected 
as	the	enzyme.	Variable	peptide	modifications	included	only	methio-
nine	 (M)	oxidation.	Other	search	parameters	used	were	 instrument	
(TripleTOF 6600), ID Focus (Biological modifications), search ef-
fort (Thorough), false discovery rate (FDR) analysis (Yes), and user- 
modified parameter files (No). The proteins were inferred based on 
the	ProGroupTM	algorithm,	which	is	associated	with	the	ProteinPilot	
software. The detected protein threshold in the software was set at 
1%	FDR.	Peptides	were	defined	as	 redundant	 if	 they	had	 identical	
amino acid sequence, cleavage site(s), and modification.
For	the	label-	free	SWATH	(sequential	window	acquisition	of	all	
theoretical fragment ion spectra) quantification, data from each 
sample was pre- processed by PeakView 2.1 (Sciex), with the default 
settings: (1) Peptide filter: # of peptides per protein: 6; peptide confi-
dence	threshold:	99%;	#	of	transitions	per	peptide:	6;	FDR	threshold:	
1%;	 (2)	Extracted	 ion	chromatogram	 (XIC)	Options:	XIC	extraction	
window	(min):	5;	XIC	width	(ppm):	75.	The	retention	time	was	cali-
brated by selecting 6 peptides with retention time across the whole 
HPLC gradient. The peak of each transition produced was then 
manually checked and curated, with only transitions detected in all 
samples	and	showing	signal	to	noise	(S/N)	>10	chosen	for	peak	area	
calculation. The peptide response was then calculated as the sum 
of all ion intensity for all curated transitions. The sum of response 
from all curated peptides in each protein was used for protein level 
quantification.	The	intensity	of	the	proteins	was	then	normalized	to	
the total ion intensity of each sample, with the ratio of protein rep-
resenting the protein level in each sample.
2.5  |  Cholesterol efflux assay
In order to determine whether changes in the HDL- bound proteins 
of interest are associated with changes in the HDL function, we 
measured the CEC of HDL as previously described by our group.3 
In summary, the HDL- CEC assays were performed using the mu-
rine macrophage cell line, J774, as per published methods.17- 19 
Briefly,	 3	 x	 105	 J774	 cells/well	 were	 plated	 and	 radiolabeled	 for	
24 h with 2 µCi of 3H-	cholesterol/ml.	ATP-	binding	cassette	 trans-
porter	A1	(ABCA1)	was	up-	regulated	by	incubation	with	0.3	mmol/L	
8-	(4-	chlorophenylthio)-	cAMP	 for	 16-	hours.	 ApoB-	depleted	 serum	
(2.8%)	 from	participants	was	added	 to	 the	efflux	medium	 for	4	h.	
Liquid scintillation counting was then added to quantify the ef-
flux of radioactive cholesterol from the cells. Efflux was calculated 
using the standard formula: (µCi of 3H- cholesterol in media contain-
ing	 2.8%	 apoB-	depleted	 participant	 plasma-	µCi	 of	 3H- cholesterol 
in plasma- free media / µCi of 3H- cholesterol in media containing 
2.8%	apoB-	depleted	pooled	control	plasma-	µCi	of	3H- cholesterol in 
pooled control plasma- free media). The pooled plasma control was 
obtained from five healthy adult volunteers and all assays were per-
formed in duplicates run at the same time.
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2.6  |  Statistical analysis
The distributions of all variables were examined prior to analysis. 
Descriptive statistics reported include frequencies and percent-
ages for categorical variables, means and standard deviations for 
normally distributed continuous variables, and medians and percen-
tiles for non- normally distributed continuous variables. To compare 
groups, either the chi- square test or Fisher's exact test was used for 
categorical	 variables,	 and	either	 the	Mann-	Whitney	 test	or	 t- tests 
were used for continuous variables. For the initial identification of 
any proteins that changed significantly after 6 months of treatment 
(among	a	total	of	84	HDL	proteins),	we	used	the	Mann-	Whitney	test	
to	compare	the	%	change	in	each	protein	 in	the	metformin	vs.	the	
placebo group. For further analysis of the selected proteins, we per-
formed T- tests on ion intensity values test to confirm our results. 
Finally,	 partial	 least	 squares	 discriminant	 analysis	 (PLS-	DA)	 with	
leave- one- out cross- validation was used to examine whether par-




3.1  |  Study population
The participants in the two treatment groups did not differ in age, 
sex, or race and all were Tanner stage V at baseline (Table 1). Baseline 
(Table	2)	and	after	6	months	(Table	3)	HbA1c,	plasma	lipids,	%	body	
fat	 and	BMI	were	not	 significantly	different	between	groups.	 In	 a	
univariate analysis, the insulin dose was significantly different be-
tween	patients	with	T1D	and	HC	(Tables	2	and	3).
3.2  |  Effect of metformin on the HDL proteome
Using	a	label-	free	SWATH	mass	spectrometry	analysis,	an	HDL	pro-
teome quantification library was generated using a subset of HDL 
samples. This library allowed for reliable detection of the relative 
abundance	 of	 84	 different	 HDL-	associated	 proteins.	 The	 Mann–	
Whitney test was used to screen measured percent changes in pro-
tein abundance among treatment groups to identify likely affected 
proteins (Table S1). This initial screen- detected differences in av-
erage percent change between placebo and metformin groups for 
six	proteins:	A2MG	(Alpha-	2-	macroglobulin),	KLKB1	(Kallikrein	B1),	
ITIH4	 (Inter-	alpha-	trypsin	 inhibitor	heavy	chain	H4),	A2AP	 (Alpha	
2- antiplasmin), PGRP2 (Peptidoglycan recognition protein), CO8G 
(Complement C8 Gamma Chain). These candidate proteins were 
then subjected to statistical analysis of raw ion intensity measure-
ments by T-	test.	With	this	analysis,	only	PGRP2	(+23.4%,	p = .0058) 
and	A2MG	and	alpha-	2-	macroglobulin	(+29.8%,	p = .049) displayed 
statistically significant increases in ion intensity in response to 
metformin	 treatment	 (Figure	 1A,B)	while	 no	 effect	was	 seen	 for	
placebo. The other four proteins were not significantly affected by 
metformin when analysed this way (Figure 1C- F). To determine if 
the cumulative minor effects of metformin on the HDL proteome 
could discriminate between treatment groups, partial least squares 
discriminant	 analysis	 (PLS-	DA)	 was	 performed.	 Discrimination	 of	
the treatment groups by changes in proteins was minimal (Figure 2) 
and	the	ROC	AUC	for	this	model	was	0.6,	only	slightly	better	than	
chance.	In	this	analysis,	A2MG	contributed	most	to	discrimination	
between treatment groups (Table S2). In our analysis, we had iden-
tified one outlier with a protein that could skew the data. We also 
performed sensitivity analysis which indicated that removal of the 
outlier point did not impact the ultimate conclusion of the statistical 
comparison.
3.3  |  Effect of metformin on CEC
To evaluate the possible impact of metformin on the most studied 
function of HDL, CEC was measured in all participants at baseline 
and 6 months follow- up. CEC of apoB- depleted plasma from each 
participant was measured using cholesterol- loaded J774 mac-
rophages	stimulated	with	cAMP	to	upregulate	ABCA1	expression.	
There was no significant difference between treatment groups at 
baseline or after 6 months of treatment with metformin or placebo 
(Figure	3).
4  |  DISCUSSION
In this analysis, from age and sex- matched youth with T1D treated 
with metformin or placebo for 6 months, we demonstrate for the 
first time that metformin has an increase on the PRGP2 (peptidogly-
can recognition protein 2 also known as N- acetylmuramoyl- L- alanine 
amidase)	and	A2MG	(Alpha-	2-	macroglobulin)	proteins	on	HDL.	The	
effect	of	metformin	on	PGRP2	and	A2MG	could	potentially	 influ-
ence HDL function and impact the cardiovascular health of T1D 
patients receiving this treatment. In this sub- study, we did not per-
form further mechanistic experiments to understand how functions 








Age	(years) 15.6 ± 1.6 15.5 ± 1.7 .87
Sex	n	(%)
Female 19	(76%) 7	(70%) .69
Male 6	(24%) 3	(30%)
Race/ethnicity	n	(%)
Hispanic 3	(12%) 1	(10%) 1
Non- hispanic white 20	(80%) 8	(80%)
Other 2	(8%) 1	(10%)
Data	displayed	are	mean	±	SD	or	n	(%).
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of HDL might be affected by enrichment of the HDL molecule with 
the	PGRP2	and	A2MG	protein.	However,	we	do	demonstrate	that	
it does not appear to involve cholesterol efflux activity, the most 
widely studied HDL function. While further experiments are needed 
to fully elucidate the mechanisms by which metformin alters PGRP2 
and	A2MG	protein	on	HDL	and	how	this	may	impact	HDL	function,	
we discuss below how our findings relate to what is known about 
HDL-	associated	PRGP2	and	A2MG	and	how	this	protein	might	con-
tribute to CVD risk.
In the current study, we found that HDL- associated PGRP2 in-
creased significantly after metformin treatment while no change was 
observed in the placebo group. Our group has previously published 
that PGRP2 was higher in the HDL of youth with T1D compared to 
healthy controls.20 This would suggest that the effect of metformin 
shifts the level of this protein even further from the level of healthy 
control	 participants	 rather	 than	 normalizing	 it	 toward	 the	 level	 of	
healthy controls. We also have shown previously that PGRP2 was 
not associated with glycemic control in youth with T1D.20 It is pos-
sible that the percent change in PRGP2 may be more closely related 
to other factors relative to the metformin use rather than glycemic 
control.	In	fact,	the	T1D-	Metformin	RCT	trial	did	not	show	any	sig-
nificant	impact	of	metformin	on	HbA1c.11 Overall, our findings sug-
gest	 that	metformin	 increases	 the	PGRP2	 and	A2MG	proteins	 on	
HDL and below we discuss the possible effects on metabolic and 
Metformin (n = 25) Placebo (n = 10)
p ValueBaseline Baseline
HbA1c	(%) 9.1 (8.4, 9.4) 8.9 (8.7, 9.1) 1
LDL- C (mg/dl) 112	(93,	128) 97 (96, 112) .6479
VLDL- C (mg/dl) 15 (10.75, 21.75) 22 (16, 26.25) .0783
HDL- C (mg/dl) 52 (44, 56) 49 (45, 59.25) 1
Triglyceride (mg/dl) 76 (56, 106) 110	(79,	132) .0828
Total cholesterol (mg/dl) 178 (157, 206) 174	(167.3,	201.5) 1
DEXA	(%	body	fat) 40	(36,	45) 39	(36,	42) .9376
BMI	(kg/m2) 30.1	(27.6,	33.0) 28.7	(26.9,	31.8) .3034
BMI	(percentile) 97.4 (94.5, 98.1) 97.0	(93.0,	97.4) .3771
BMI	Z-	score 1.94 (1.60, 2.08) 1.88 (1.48, 1.94) .3807
DEXA	%	fat 40	(36,	45) 39	(36,	42) .9376
Waist circumference(cm) 94.9 (88.8, 104.0) 95.3	(91.0,	101.9) .9273
Insulin dose (units/kg/day) 0.96 (0.85, 1.05) 1.21	(1.03,	1.38) .0207
Note: Values	are	reported	as	median	(25th	%ile,	75th	%ile).	p- values were calculated using the 
Mann-	Whitney	test.
TA B L E  2 The	biochemical	and	clinical	
variables at baseline by group
Metformin (n = 25) Placebo (n = 10)
p Value6 months 6 months
HbA1c	(%) 8.8 (8.0, 9.4) 9.0	(8.3,	9.9) .3235
LDL- C (mg/dl) 113	(90,	122) 100 (92, 114) .6919
VLDL- C (mg/dl) 14.5 (11.0, 20.0) 17.5 (12.0, 20.0) .4591
HDL- C (mg/dl) 53.0	(44.0,	60.0) 47.5 (41.0, 56.8) .3594
Triglyceride (mg/dl) 71.0 (54.8, 99.0) 88.5 (61.8, 98.0) .4609
Total cholesterol (mg/dl) 179	(160,	193) 172 (157, 188) .5838
DEXA	(%	body	fat) 41	(37,	44) 40	(35,	43) .6698
BMI	(kg/m2) 30.1	(26.9,	32.7) 29.0	(26.6,	32.0) .6275
BMI	(percentile) 96.1 (94.5, 98.1) 95.7	(93.8,	97.8) .7060
BMI	z 1.76 (1.60, 2.07) 1.73	(1.55,	2.01) .7149
DEXA	%	fat 41	(37,	44) 40	(35,	43) .6698
Waist circumference(cm) 93.5	(88.9,	101.5) 92	(82.3,	105.3) .7150
Insulin dose (units/kg/day) 0.82 (0.68, 0.95) 1.12 (0.92, 1.28) <.001
Note: Values are reported as median (25th	%ile,	75th	%ile).	p-	values	were	calculated	using	the	Mann-	
Whitney test.
TA B L E  3 The	biochemical	and	clinical	
variables at 6 months by group
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cardiovascular health based on what is known so far about the func-
tion of these proteins.
Interestingly, one study found that patients with the acute 
coronary syndrome had lower expression of PGRP2 levels in HDL 
compared to patients with stable coronary disease, even though 
no difference was found when compared to HDL levels of healthy 
controls.21 These patients were older men, with and without cor-
onary	 disease	 and	 only	 1/30	participants	 had	 diabetes.	 It	 is	 likely	
that age, sex and diabetes status might further explain alterations of 
PRGP2	levels	in	HDL.	Also,	the	peptidoglycan	recognition	protein	1,	
(PGRP1), which belongs to the same family of proteins, was found 
to be associated with atherosclerotic cardiovascular events in the 
Dallas Heart Study and participants with the highest levels of PGRP1 
were	>3	times	more	likely	to	develop	CVD.22
Peptidoglycan recognition proteins are known to be responsi-
ble for keeping a normal gut microbiome environment and protect 
the host from inflammation and colitis.23 PGRP2 is present in the 
serum, the skin and the epithelial cells of the intestines.24 The ex-
pression of PGRP2 is highest in the liver, from where it is secreted in 
the blood, and PGRP2 expression is also induced by bacteria in the 
F I G U R E  1 Effect	of	6-	month	placebo	
or metformin treatment on HDL- 
associated proteins. Ion intensity values 
detected by data- independent acquisition 
(DIA)	mass	spectrometry	analysis	of	size-	
exclusion chromatography purified HDL 
were compared for subjects receiving 
placebo or metformin for 6 months. T- 
tests were used for statistical comparison 
between baseline and 6- month time 
points within each treatment group. * 
indicates p < .05; ** indicates p < .01; no 
indicator is present where comparisons 
are	not	statistically	significant.	A2MG:	
alpha- 2- macroglobulin, ITIH4: inter- 
alpha- trypsin inhibitor heavy chain 
family member 4, KLKB1: kallikrein B1, 
A2AP:	alpha-	2-	antiplasmin,	PGRP2:	







F I G U R E  2 Plot	from	PLS-	DA	for	
protein changes by treatment group. 
Partial least squares discriminant analysis 
(PLS-	DA)	was	used	to	determine	if	the	
cumulative effects of metformin on 
the HDL proteome could be used to 
distinguish	treatment	groups.	Mass	
spectrometry ion intensities from all 
84 quantified proteins were used as 
input variables for the model. Rankings 
of the top 10 weighted proteins from 
components 1 and 2 are listed in 
Table S2
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epithelial cells of all segments of the gastrointestinal tract.23 There 
is growing evidence about the role of altered gut microbiota to pro-
mote CVD via several mechanisms, such as altering lipid metabolism, 
playing a role in vascular dysfunction and hypertension, increasing 
systemic inflammation, foam cell formation and insulin resistance.25 
There is recent evidence that treatment with metformin not only al-
ters the gut microbiome but some of the beneficial effects of met-
formin could be due to the change in the gut microbiome.26,27 It is 
also known that the intestine has a significant contribution to the 
production of HDL- C.28 Based on the above, it is possible that met-
formin alterations to the gut microbiome could be associated with 
changes in the peptidoglycan protein expression of PRGP2 in the 
intestines and also on PRGP2 concentration on HDL.
We	also	found	that	A2MG	increased	after	metformin.	Our	group	
has	previously	found	that	the	A2MG	protein	of	HDL	was	positively	
associated with calcified burden of coronary angiography, a marker 
of increased CVD risk.29	 Another	 group	 also	 found	 higher	 A2MG	
protein of HDL in patients with non- alcoholic fatty liver disease, 
suggestive of increased fibrinogenesis activity.30	More	 research	 is	
needed to explore whether metformin changes the anti- thrombotic 
function	of	HDL	by	altering	the	expression	of	A2MG	protein.
Our study did not find any effects of metformin on HDL efflux 
capacity,	contrary	 to	our	hypothesis.	A	previous	study	by	Matsuki	
et al31 showed that glycation of HDL reduced the CEC of HDL and 
that metformin restored this defect in studies done in vitro, by pre-
venting the glycation of HDL. One possible explanation for the dif-
ference with our findings is that the dose used for the in vitro studies 
was relatively higher and had a more potent effect than the dose 
that has been approved for use in humans. In addition, in our study, 
all	 patients	had	diabetes	with	 a	HbA1c	well	 above	 target,	 and	we	
thus assume that a certain degree of glycation of HDL was present 
in all of them. However, our study was not designed to look at the 
glycated forms of HDL. It is possible that the effect of metformin 
in restoring CEC might be different in certain patient populations 
with a high degree of glycated HDL. Future studies can examine 
the factors that affect the glycation of proteins of HDL in patients 
with T1D and whether metformin or other diabetes drugs such as 
insulin could restore the CEC of glycated forms of HDL in patients 
with T1D. Further studies are needed to examine the exact role of 
PRGP2	and	A2MG	on	HDL	function	and	whether	metformin's	effect	




alpha-	2-	macroglobulin,	 KLKBI,	 Kallikrein	 B1,	 and	 A2AP,	 Alpha	
2- antiplasmin. These pathways are involved in the pathogenesis 
of atherosclerosis and coagulation, which supports the hypothesis 
that changes in these proteins could affect the anti- thrombotic HDL 
function.32 Our group had also previously found that KLKB1 of HDL 
was associated with lower CEC.29 However, given that KLKBI and 
A2AP	proteins	 also	 increased	 in	 some	participants	 in	 the	 placebo	
group (Figure 1), we believe more research is needed to explore 
whether metformin changes the anti- thrombotic function of HDL by 
altering the expression of the above proteins.
Strengths of our study include the fact that we were able to 
match participants that were treated with metformin or placebo in 
a	 double-	blinded	 randomized	 fashion.	 All	 participants	 were	 over-
weight and had similar glycemic control and pubertal stage. We 
also	have	detailed	HDL	proteome	data:	The	two-	step	size-	exclusion	
chromatography and lipid interaction- based HDL purification and 
the	 SWATH-	MS	 allowed	 us	 to	 have	 a	 very	 sensitive	 and	 robust	
label- free proteomic quantitation for multiple clinical samples. Our 
two- step approach to the proteomics data analysis included an ini-
tial screening for metformin affected proteins based on percent 
change by treatment group and was followed up with direct com-
parisons of candidate proteins by their detected ion intensities. This 
approach improved confidence in detected differences and reduced 
the false discovery rate by filtering out weaker effects. Limitations 
of	this	study	include	our	small	sample	size	and	the	lack	of	additional	
HDL function assays or assays directly related to PGRP2 function 
and	the	lack	of	directly	measured	insulin	sensitivity.	A	limitation	of	
our HDL purification method is that it does not allow for analysis 
of	HDL	subfractions	which	are	commonly	characterized	by	density	
and isolated by ultracentrifugation.33 One advantage of our ap-
proach over ultracentrifugation is that it purifies HDL under phys-
iological g forces and salt conditions resulting in less disruption of 
protein interactions on lipoproteins caused by extreme conditions 
experienced during ultracentrifugation.34,35 The downside is that 
size-	exclusion	chromatography	by	itself	does	not	isolate	pure	HDL	
preparations and there is some contamination of non- lipoprotein- 
associated proteins (e.g. albumin and immunoglobulins). This is 
overcome by our two- step isolation, which includes washing of li-
poproteins on a lipid- binding resin.13	Alternative	approaches	to	the	
isolation of native HDL include immunoaffinity adsorption usually 
by	pulldown	with	anti-	apolipoprotein	A-	I	antibodies.36,37 This tech-
nique produces clean HDL, but it is not known if some HDL- binding 
F I G U R E  3 Effect	of	placebo	or	metformin	on	cholesterol	
efflux capacity. Cholesterol efflux to apoB- depleted serum was 
measured	using	cAMP-	treated	J774	macrophage	cells	loaded	
with	radiolabeled	cholesterol.	Efflux	was	normalized	to	a	healthy	
control sample pool. Data were analysed using repeated measures 
two-	way	ANOVA	with	Sidak	correction	for	multiple	comparisons.	
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on the proteomic composition of HDL and identify associations with 
changes in cholesterol efflux function. Even though we did not find 
a significant change in CEC, it is possible this was due to our rela-
tively	small	sample	size	or	that	the	treatment	did	not	have	an	impact	
on pre- beta HDL, the particle species predominantly responsible 
for	ABCA1-	mediated	 cholesterol	 efflux.38 Pre- beta HDL are small 
discoidal	 particles	 composed	 of	 apolipoprotein	 A-	I,	 phospholipid,	
and free cholesterol, and they do not contain many other proteins.39 
Therefore, effects observed in the HDL proteome are likely not 
reflective	of	 changes	 to	pre-	beta	particles.	Although	 it	 is	 possible	
that	redistribution	of	apoA-	I	or	other	proteins	among	HDL	subspe-
cies	could	occur	even	 if	no	change	 in	the	total	apoA-	I	protein	was	
observed. However, this could not be detected without isolation of 
distinct HDL subfractions. It is also possible that there may be in-
teresting glycation modifications to HDL proteins that could impact 
particle functions and might be prevented or reversed by metformin, 
but we were unable to examine these in the present analysis. Future 
studies can further explore whether enrichment of HDL with PRGP2 
could potentially alter HDL function.




quantitation. Further studies are needed to explore whether this ef-
fect of metformin impacts other known functions of HDL such as 
the anti- inflammatory or anticoagulant activity, and to also explore 
potential novel functions arising from this interaction. With the re-
cent rapid advancements in proteomics technologies, future studies 
to investigate the factors that contribute to the glycation of HDL 
proteins in patients with T1D and how those are impacted by met-
formin or other diabetes drugs will be of significant interest.
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